Literature DB >> 2128278

Inactivity of terbinafine in a rat model of pulmonary aspergillosis.

H J Schmitt1, J Andrade, F Edwards, Y Niki, E Bernard, D Armstrong.   

Abstract

In a model of bronchopulmonary aspergillosis terbinafine did not improve survival of experimental animals in doses up to 80 mg/kg/day despite adequate lung concentrations. Pretreatment and aerosolization of the compound were also ineffective. Terbinafine was markedly less active in vitro when serum was used instead of Yeast-Nitrogen-Glucose-broth. It is concluded that a lack of bioavailability in the presence of serum may explain the lack of activity of terbinafine in experimental aspergillosis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2128278     DOI: 10.1007/bf01967386

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  13 in total

1.  In-vitro studies with SF 86-327, a new orally active allylamine derivative.

Authors:  S Shadomy; A Espinel-Ingroff; R J Gebhart
Journal:  Sabouraudia       Date:  1985-04

2.  Synthesis and antifungal activity of (E)-N-(6,6-dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphtha lenemethanamine (SF 86-327) and related allylamine derivatives with enhanced oral activity.

Authors:  A Stütz; G Petranyi
Journal:  J Med Chem       Date:  1984-12       Impact factor: 7.446

3.  Effect of the antimycotic drug naftifine on growth of and sterol biosynthesis in Candida albicans.

Authors:  N S Ryder; G Seidl; P F Troke
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

4.  Antifungal activity of the allylamine derivative terbinafine in vitro.

Authors:  G Petranyi; J G Meingassner; H Mieth
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

5.  MIC and fungicidal activity of terbinafine against clinical isolates of Aspergillus spp.

Authors:  H J Schmitt; E M Bernard; J Andrade; F Edwards; B Schmitt; D Armstrong
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

6.  An approach to intensive antileukemia therapy in patients with previous invasive aspergillosis.

Authors:  J E Karp; P A Burch; W G Merz
Journal:  Am J Med       Date:  1988-08       Impact factor: 4.965

7.  Inhibition of squalene epoxidase by allylamine antimycotic compounds. A comparative study of the fungal and mammalian enzymes.

Authors:  N S Ryder; M C Dupont
Journal:  Biochem J       Date:  1985-09-15       Impact factor: 3.857

8.  Pharmacokinetics of aerosol amphotericin B in rats.

Authors:  Y Niki; E M Bernard; H J Schmitt; W P Tong; F F Edwards; D Armstrong
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

9.  Activity of terbinafine in experimental fungal infections of laboratory animals.

Authors:  G Petranyi; J G Meingassner; H Mieth
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

10.  Aerosol amphotericin B is effective for prophylaxis and therapy in a rat model of pulmonary aspergillosis.

Authors:  H J Schmitt; E M Bernard; M Häuser; D Armstrong
Journal:  Antimicrob Agents Chemother       Date:  1988-11       Impact factor: 5.191

View more
  8 in total

1.  Effects of serum on in vitro susceptibility testing of echinocandins.

Authors:  Zekaver Odabasi; Victor Paetznick; John H Rex; Luis Ostrosky-Zeichner
Journal:  Antimicrob Agents Chemother       Date:  2007-09-04       Impact factor: 5.191

2.  Susceptibility testing of Aspergillus flavus: inoculum dependence with itraconazole and lack of correlation between susceptibility to amphotericin B in vitro and outcome in vivo.

Authors:  J Mosquera; P A Warn; J Morrissey; C B Moore; C Gil-Lamaignere; D W Denning
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

3.  Use of terbinafine in mouse and rat models of Pneumocystis carinii pneumonia.

Authors:  Peter D Walzer; Alan Ashbaugh
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

4.  Efficacy of antifungal therapy in a nonneutropenic murine model of zygomycosis.

Authors:  Eric Dannaoui; Johan W Mouton; Jacques F G M Meis; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

Review 5.  Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses.

Authors:  J A Balfour; D Faulds
Journal:  Drugs       Date:  1992-02       Impact factor: 9.546

6.  Influence of serum protein binding on the in vitro activity of anti-fungal agents.

Authors:  M Schäfer-Korting; H C Korting; W Rittler; W Obermüller
Journal:  Infection       Date:  1995 Sep-Oct       Impact factor: 3.553

7.  In vitro interactions of approved and novel drugs against Paecilomyces spp.

Authors:  Montserrat Ortoneda; Javier Capilla; F Javier Pastor; Isabel Pujol; Clara Yustes; Carolina Serena; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

Review 8.  Inhaled Antifungal Agents for Treatment and Prophylaxis of Bronchopulmonary Invasive Mold Infections.

Authors:  Kévin Brunet; Jean-Philippe Martellosio; Frédéric Tewes; Sandrine Marchand; Blandine Rammaert
Journal:  Pharmaceutics       Date:  2022-03-14       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.